The Chicago Breast Cancer SPORE program brings together a multidisciplinary team of basic, clinical and population science investigators at the University of Chicago to design innovative research that will reduce the """"""""pain and suffering"""""""" from breast cancer using a uniquely global strategy. The translational research projects chosen represent extensions of funded research being conducted by SPORE investigators. The science of the SPORE consists of four translational research projects. ? ? Project 1 """"""""Estimation of Breast Cancer Risk from Mammography and Breast MRI"""""""" will develop multi-modality, image-based markers for assessing breast density and parenchymal structure that may be used alone or in combination with clinical measures and other biomarkers to quantify breast cancer risk and for monitoring response to chemopreventive agents. Project 2 """"""""Specificity of MRI with optimal temporal, spatial, and spectral sampling in early breast cancer"""""""" will examine whether MR imaging with improved spectral, temporal and spatial sampling (MRITSS) leads to improved anatomic and functional imaging in the high-risk population that would benefit most from MRI. Project 3: """"""""Variation in hormone and xenobiotic metabolizing enzyme genes and breast cancer risk"""""""" will determine whether sequence variation in genes involved in the metabolism of sex hormones and xenobiotics influence the risk to breast cancer using resources from existing case-control cohorts that are highly enriched for women of African ancestry with ER negative breast cancer. Project 4: """"""""ldentifying population specific variants important in toxicity to breast cancer chemotherapy"""""""" to identify genetic variation in target genes that result in an increased risk of toxicities using capecitabine and platinating agents as model drugs. We will identify genetic variants that dictate phenotypes including cytotoxicity and apoptosis by utilizing EBV-transformed lymphoblastoid cell lines from related healthy Caucasians and follow up with studies in African Americans and Yoruban trios from Nigeria. These research projects will be supported by three scientific cores: Core 1: SPORE Administration, Core 2: Biospecimens, Pathology and Genotyping, and Core 3: Analytic and Bioinformatics Core. A Developmental Research Program will advance the rapid translation of the most promising scientific discoveries to the clinic and support the reverse translation of clinical observations in the laboratory. A Career Development Program will be used to support the transition of the most promising junior faculty investigators and to recruit new senior investigators into breast cancer translational research. The investigators, core facilities, the career development and the developmental research programs in the SPORE are all integrated into the University of Chicago Cancer Research Center and, collectively, will translate scientific advances into substantial improvement in breast cancer outcomes. ? ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (O1))
Program Officer
Kuzmin, Igor A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Guindalini, Rodrigo Santa; Zheng, Yonglan; Abe, Hiroyuki et al. (2018) Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers. Clin Cancer Res :
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Zheng, Yonglan; Walsh, Tom; Gulsuner, Suleyman et al. (2018) Inherited Breast Cancer in Nigerian Women. J Clin Oncol 36:2820-2825
Wang, Shengfeng; Ogundiran, Temidayo; Ademola, Adeyinka et al. (2018) Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiol Biomarkers Prev 27:636-643
Debiasi, Márcio; Polanczyk, Carisi A; Ziegelmann, Patrícia et al. (2018) Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol 8:156
Feng, Ye; Rhie, Suhn Kyong; Huo, Dezheng et al. (2017) Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiol Biomarkers Prev 26:1016-1026
Hamdi, Yosr; Soucy, Penny; Kuchenbaeker, Karoline B et al. (2017) Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat 161:117-134
Michailidou, Kyriaki (see original citation for additional authors) (2017) Association analysis identifies 65 new breast cancer risk loci. Nature 551:92-94
Rudin, Shoshana; Marable, Marcus; Huang, R Stephanie (2017) The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. Genomics Proteomics Bioinformatics 15:82-93
Geeleher, Paul; Huang, R Stephanie (2017) Exploring the Link between the Germline and Somatic Genome in Cancer. Cancer Discov 7:354-355

Showing the most recent 10 out of 203 publications